• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4173.TWO
Share

Arich Enterprise Co., Ltd. Stocks

NT$ 17.9Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 41.30M

NT$ 17.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1969 and headquartered in New Taipei City, Taiwan, Arich Enterprise Co., Ltd. specializes in the marketing, promotion, and distribution of pharmaceutical products across Taiwan. Their portfolio includes both prescribed medications and over-the-counter drugs. Furthermore, the company extends its services to include a full suite of logistics operations for the pharmaceutical sector. These encompass inventory management for drug manufacturers, systematic distribution, handling of customer concerns, national transportation, and secure warehousing. Arich serves a diverse customer base, including hospitals, medical clinics, independent pharmacies, large retail drugstore chains, and hypermarkets.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 19:59

Sam Altman didn't believe in a four-hour workweek made possible by AI. Why?

27.07.2026 19:16

Freedom was the first on Wall Street to believe in Intrepid, a small-cap potash producer. Why?

27.07.2026 18:47

A lull in the war in the Middle East boosted U.S. stocks: The Dow rose more than 1%

27.07.2026 18:30

A 10-fold growth, Korea’s golden age, and a lesson from China: Highlights from an interview with the head of Nvidia

27.07.2026 18:02

A Magnet for Startups: Why Are Fintech Startups and Neobanks Flocking to Colombia?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026